For 45 of them, it was possible to evaluate whether the primary endpoint was achieved (transfusion independence ≥12 consecutive months while maintaining a weighted average Hb ≥9 g/dL assessed starting 60 days after the last RBC transfusion for post-transplant support or transfusion thalassemia management). This evidence concerns the gene GSTM1 and thalassemia.